• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by AEON Biopharma Inc.

    5/30/25 12:10:37 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEON alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    AEON Biopharma, Inc.

    (Name of Issuer)


    Common

    (Title of Class of Securities)


    00791X209

    (CUSIP Number)


    05/27/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00791X209


    1Names of Reporting Persons

    Chernett Jorey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,128,500.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,128,500.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,128,500.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AEON Biopharma, Inc.
    (b)Address of issuer's principal executive offices:

    5 PARK PLAZA, SUITE 1750, IRVINE, CALIFORNIA, 92614.
    Item 2. 
    (a)Name of person filing:

    Jorey Chernett
    (b)Address or principal business office or, if none, residence:

    6222 Indianwood Trail, Bloomfield Hills, MI 48301
    (c)Citizenship:

    US
    (d)Title of class of securities:

    Common
    (e)CUSIP No.:

    00791X209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,128,500
    (b)Percent of class:

    9.98%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,128,500

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    1,128,500

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Chernett Jorey
     
    Signature:/s/Jorey Chernett
    Name/Title:Individual
    Date:05/30/2025
    Get the next $AEON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AEON

    DatePrice TargetRatingAnalyst
    8/18/2023$18.00Buy
    H.C. Wainwright
    More analyst ratings

    $AEON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on AEON Biopharma with a new price target

      H.C. Wainwright initiated coverage of AEON Biopharma with a rating of Buy and set a new price target of $18.00

      8/18/23 8:03:13 AM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

      IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today reported the grant in May of 102,880 restricted stock units (RSUs) of the Company's common stock to newly hired non-executive employees of the company. The awards were approved by the Company's Board of Directors under the AEON 2025 Inducement Incentive Plan, which a grant date and vesting commencement date of May 21, 2025. The RSUs vest over four years, 25% on each annual anniversary of the vesting commencement date. The awards are

      5/23/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

      IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON's President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. Please register here to attend the conference on Wednesday, May 21st. About AEON Biopharma AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabot

      5/19/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – – Appointed Rob Bancroft as the Company's President and Chief Executive Officer; Mr. Bancroft also joined AEON's Board of Directors – IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum

      5/14/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AEON Biopharma Inc.

      SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

      11/14/24 5:05:14 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Leadership Updates

    Live Leadership Updates

    See more
    • AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

      IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in connection with the appointment of Rob Bancroft as President and Chief Executive Officer, the Company's Compensation Committee of the Board of Directors has approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bancroft of a non-qualified stock option to purchase 59,034 shares of AEON Class A common stock under AEON's 2025 Employment Inducement Incentive Award Plan (the "I

      4/21/25 4:10:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

      IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Mr. Bancroft will also join AEON's Board of Directors. "We are excited to welcome Rob as the new President and Chief Executive Officer of AEON. He is an exceptional leader who brings a wealth of experience in the therapeutic toxin industry, and a strong track record of building value through the execution of well-defined s

      4/21/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Announces CEO Transition

      – Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to pursue another opportunity, effective April 4, 2025. Mr. Forth will continue with the Company as a member of it

      3/27/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Thunen Shelley B

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/23/25 5:04:47 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Exec VP, CLO & Corp Secretary Wilson Alexander Blair

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/23/25 4:57:12 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Oh Chad

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/23/25 4:56:33 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by AEON Biopharma Inc.

      SCHEDULE 13G - AEON Biopharma, Inc. (0001837607) (Subject)

      5/30/25 12:10:37 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AEON Biopharma, Inc. (0001837607) (Filer)

      5/20/25 4:04:52 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AEON Biopharma Inc.

      SCHEDULE 13G/A - AEON Biopharma, Inc. (0001837607) (Subject)

      5/15/25 7:21:07 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Financials

    Live finance-specific insights

    See more
    • AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – – Appointed Rob Bancroft as the Company's President and Chief Executive Officer; Mr. Bancroft also joined AEON's Board of Directors – IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum

      5/14/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

      – ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not meet statistical significance vs. placebo because of a much higher-than-expected placebo response of 4.2 days – – Study demonstrated statistical significance on multiple secondary and exploratory endpoints, including the responder analysis of both a >50% and >75% improvement from baseline in MMD – – Totality of the data showed evidence of a dose response favoring the higher 195 units arm, and supports the decision to advance into Phase 3, anticipated in 2H 2024 – – Ongoing Phase 2 trial for the

      10/19/23 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fischer Jost bought $29,250 worth of shares (60,000 units at $0.49), increasing direct ownership by 29% to 266,785 units (SEC Form 4)

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/23/25 4:46:16 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fischer Jost bought $55,300 worth of shares (110,000 units at $0.50), increasing direct ownership by 114% to 206,785 units (SEC Form 4)

      4 - AEON Biopharma, Inc. (0001837607) (Issuer)

      5/21/25 4:50:20 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care